NICE Recommends Mirikizumab (Omvoh ▼) for Previously Treated Moderately to Severely Active Crohn's Disease 1 - Pharmafile

Comparative analysis of natural language processing methodologies for classifying computed tomography enterography reports in Crohn’s disease patients

Imaging is crucial to assess disease extent, activity, and outcomes in inflammatory bowel disease (IBD). Artificial intelligence (AI) image interpretation requires automated exploitation of studies at scale as an initial step. Here we evaluate natural language processing to classify Crohn’s disease (CD) on CTE. From our population representative IBD registry a sample of CD patients (male: 44.6%, median age: 50 IQR37-60) and controls (n = 981 eac…

NICE recommends mirikizumab (Omvoh ▼) for previously treated moderately to severely active Crohn's disease 1 - Pharmafile

In the Phase 3 VIVID-1 trial, patients treated with mirikizumab experienced significant improvement in clinical remission and endoscopic response at one year 2 Among those who achieved endoscopic response at one year, 88% of patients maintained endoscopic response at two years of continuous mirikizumab treatment in open-label extension 3 BASINGSTOKE, May 30, 2025 – Today, […] The post NICE recommends mirikizumab (Omvoh ▼) for previously treated …